Drug Landscape ›
Influenza vaccine ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 2,697
Most-reported reactions
Dyspnoea — 364 reports (13.5%) Pyrexia — 298 reports (11.05%) Fatigue — 290 reports (10.75%) Cough — 283 reports (10.49%) Nausea — 280 reports (10.38%) Pain — 265 reports (9.83%) Chronic Obstructive Pulmonary Disease — 242 reports (8.97%) Malaise — 237 reports (8.79%) Headache — 229 reports (8.49%) Drug Interaction — 209 reports (7.75%)
Source database →
Influenza vaccine in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Influenza vaccine approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Influenza vaccine in United States?
University of Wisconsin, Madison is the originator. The local marketing authorisation holder may differ — check the official source linked above.